
JBIO Stock Forecast & Price Target
JBIO Analyst Ratings
Bulls say
Jade Biosciences is positioned for success as they continue to progress through the clinical trials for their drug JADE101, with positive initial results and plans for a more convenient dosing schedule. The company's pipeline of other potential treatments also adds to their promising outlook.
Bears say
Jade Biosciences is a clinical-stage biotechnology company with a promising pipeline but lacks upcoming key data and financial projections. While the Phase 1 results for JADE101 are encouraging, it will not be until the Phase 2 JUNIPER study in 2027 that the true potential of this candidate can be seen. Additionally, the company may face challenges in gaining regulatory approval and competition from other companies in the IgA nephropathy space.
This aggregate rating is based on analysts' research of Aerovate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
JBIO Analyst Forecast & Price Prediction
Start investing in JBIO
Order type
Buy in
Order amount
Est. shares
0 shares